BACKGROUND: Medium Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency is an autosomal recessive disorder of fatty acid oxidation, with potential fatal outcome. MCAD deficiency is diagnosed by acylcarnitine analysis on newborn screening blood spot cards by tandem mass spectrometry. Early diagnosis of MCAD and presymptomatic treatment can potentially reduce morbidity and mortality. OBJECTIVES: To evaluate incidence, clinical outcome, biochemical and molecular phenotype of MCAD cases detected in the first three years of newborn screening in British Columbia (BC). METHODS AND RESULTS: Medium chain length acylcarnitines, octanoylcarnitine (C8) and decanoylcarnitine (C10), were measured on newborn screening blood spot cards. Out of 121,000 live births, 17 newborns had C8 values above the screening cut-off of 0.38 umol/L. Ten newborns had elevated C8 on repeat cards and were investigated further. Both C8 and C8/C10 ratios remained abnormal in all confirmed MCAD cases. Positive predictive value of screening was 58% with no false negative results. Seven patients were homozygous for the common c.985A > G MCAD mutation and three others were compound heterozygous for the c.985A > G and a second mutation. Two novel mutations were identified (c.260T > C and c.382T > A). The estimated incidence of MCAD was approximately 1:12,000 live births. Upon frequent feeding and carnitine supplementation, none of the patients had metabolic crises or adverse outcomes. CONCLUSION: Frequency of MCAD in BC is comparable to reports from other newborn screening programs. Persistence of elevated C8 levels and C8/C10 ratios in confirmed MCAD cases suggest that these are sensitive markers for newborn screening. Early detection and treatment have successfully prevented adverse health outcomes in patients with MCAD.
BACKGROUND: Medium Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency is an autosomal recessive disorder of fatty acid oxidation, with potential fatal outcome. MCAD deficiency is diagnosed by acylcarnitine analysis on newborn screening blood spot cards by tandem mass spectrometry. Early diagnosis of MCAD and presymptomatic treatment can potentially reduce morbidity and mortality. OBJECTIVES: To evaluate incidence, clinical outcome, biochemical and molecular phenotype of MCAD cases detected in the first three years of newborn screening in British Columbia (BC). METHODS AND RESULTS: Medium chain length acylcarnitines, octanoylcarnitine (C8) and decanoylcarnitine (C10), were measured on newborn screening blood spot cards. Out of 121,000 live births, 17 newborns had C8 values above the screening cut-off of 0.38 umol/L. Ten newborns had elevated C8 on repeat cards and were investigated further. Both C8 and C8/C10 ratios remained abnormal in all confirmed MCAD cases. Positive predictive value of screening was 58% with no false negative results. Seven patients were homozygous for the common c.985A > G MCAD mutation and three others were compound heterozygous for the c.985A > G and a second mutation. Two novel mutations were identified (c.260T > C and c.382T > A). The estimated incidence of MCAD was approximately 1:12,000 live births. Upon frequent feeding and carnitine supplementation, none of the patients had metabolic crises or adverse outcomes. CONCLUSION: Frequency of MCAD in BC is comparable to reports from other newborn screening programs. Persistence of elevated C8 levels and C8/C10 ratios in confirmed MCAD cases suggest that these are sensitive markers for newborn screening. Early detection and treatment have successfully prevented adverse health outcomes in patients with MCAD.
Authors: Esther M Maier; Bernhard Liebl; Wulf Röschinger; Uta Nennstiel-Ratzel; Ralph Fingerhut; Bernhard Olgemöller; Ulrich Busch; Nils Krone; Rüdiger v Kries; Adelbert A Roscher Journal: Hum Mutat Date: 2005-05 Impact factor: 4.878
Authors: B S Andresen; P Bross; S Udvari; J Kirk; G Gray; S Kmoch; N Chamoles; I Knudsen; V Winter; B Wilcken; I Yokota; K Hart; S Packman; J P Harpey; J M Saudubray; D E Hale; L Bolund; S Kølvraa; N Gregersen Journal: Hum Mol Genet Date: 1997-05 Impact factor: 6.150
Authors: T H Zytkovicz; E F Fitzgerald; D Marsden; C A Larson; V E Shih; D M Johnson; A W Strauss; A M Comeau; R B Eaton; G F Grady Journal: Clin Chem Date: 2001-11 Impact factor: 8.327
Authors: B S Andresen; S F Dobrowolski; L O'Reilly; J Muenzer; S E McCandless; D M Frazier; S Udvari; P Bross; I Knudsen; R Banas; D H Chace; P Engel; E W Naylor; N Gregersen Journal: Am J Hum Genet Date: 2001-05-08 Impact factor: 11.025
Authors: J L Van Hove; W Zhang; S G Kahler; C R Roe; Y T Chen; N Terada; D H Chace; A K Iafolla; J H Ding; D S Millington Journal: Am J Hum Genet Date: 1993-05 Impact factor: 11.025
Authors: B S Andresen; T G Jensen; P Bross; I Knudsen; V Winter; S Kølvraa; L Bolund; J H Ding; Y T Chen; J L Van Hove Journal: Am J Hum Genet Date: 1994-06 Impact factor: 11.025
Authors: Melanie B Gillingham; Matthew Hirschfeld; Sarah Lowe; Dietrich Matern; James Shoemaker; William E Lambert; David M Koeller Journal: Mol Genet Metab Date: 2011-06-28 Impact factor: 4.797